TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03771066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bisphenol A
Description: Vanilla wafer cookie with bisphenol A administered

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vanilla wafer cookie with no bisphenol A
Study: NCT02138162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: oral
Study: NCT01808365

Intervention type: PROCEDURE
Intervention: Posterior pharyngeal swab
Description: Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.

Intervention type: OTHER
Intervention: Data collection
Description: Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
Study: NCT00003992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study: NCT01940549

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Trauma Focused Therapy + tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Focused Therapy + tDCS
Study: NCT00505544

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that ask about your sleep, symptoms, and mood.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that ask about your sleep, symptoms, and mood.

Intervention type: DEVICE
Intervention: Actigraph
Description: Wear actigraph to collect information on activity levels and sleep patterns for one week.
Study: NCT02813434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: florbetapir
Description: 18F-AV-45 or 18F-Florbetapir
Study: NCT00784459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Treatment with abatacept, 10 mg/kg IV, for 5 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Placebo, IV
Study: NCT01957215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Topical indomethacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study: NCT01875666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg IV, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg IV, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg IV, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pertuzumab
Description: 840 mg IV single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pertuzumab
Description: 840 mg IV single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: 1000 mg daily for 7 days
Study: NCT04532281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Murine CD19 CAR-T cells
Description: Each subject receive murine CD19 CAR T-cells by intravenous infusion
Study: NCT04513106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP programme Have a Say
Description: It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-control health talks
Description: Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
Study: NCT02668328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory Tailored Behavioral Intervention
Description: The intervention will enhance self-efficacy
Study: NCT04493489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCG
Description: Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG
Description: Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
Study: NCT02788851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine
Description: Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine
Description: Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
Study: NCT02064829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IG-001
Description: 260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
Study: NCT02613338

Intervention type: DEVICE
Intervention: DePuy Attune posterior stabilizing fixed bearing knee system
Description: Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
Study: NCT02986425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIP intervention
Description: The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
Study: NCT03611946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rZIKV/D4Δ30-713 (Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection)
Description: Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rZIKV/D4Δ30-713 (Administered at a dose of using 10^4 plaque-forming units (PFUs) by subcutaneous injection).
Description: Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
Study: NCT03600220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: antihypertension drug, acupuncture twice a week for 3 months
Study: NCT03083964

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming
Description: The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
Study: NCT00520091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT- 11
Description: 65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT- 11
Description: 65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery will occur prior to chemoradiation therapy for those patients with resectable disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
Study: NCT01335438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless (Nexgen)
Description: Cementless fixation of Nexgen CR TKR

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented (Nexgen)
Description: Cemented fixation of Nexgen CR TKR
Study: NCT01172561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Advisor Education Intervention
Description: The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
Study: NCT00554346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia(etoricoxib 90 mg/tablet)
Description: Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arcoxia(etoricoxib 90 mg/tablet)
Description: Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
Study: NCT01979328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plaster cast
Study: NCT00698139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Pacemaker
Description: Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Pacemaker
Description: Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Pacemaker
Description: Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
Study: NCT03185169

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Replens and coconut oil
Study: NCT03670693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA scan)
Description: Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
Study: NCT04366128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPA indution immunotherapy
Description: 1. Camelirumab 200mg Intravenous injection on day 1.~2. Apatinib 250mg taken orally once daily.~3. Pegaspargase 2000U/m2 Intramuscular injection on day 1.
Study: NCT01962116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate 4%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: unfractionated heparin
Study: NCT02916628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group counseling
Description: Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: group counseling
Description: Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: Auricular acupressure using acupellets was performed for 6 weeks continuously

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo acupressure
Description: Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
Study: NCT01080625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: 100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
Study: NCT02021240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01080625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: 10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: 10ml of normal saline is administered at the time of reperfusion
Study: NCT03670693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA scan)
Description: Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA scan)
Description: Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Supine cardiorespiratory fitness assessment
Description: VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Supine cardiorespiratory fitness assessment
Description: VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Supine cardiorespiratory fitness assessment
Description: VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI Exercise assessment
Description: Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI Exercise assessment
Description: Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
Study: NCT03022604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C4/Generation 4
Description: 12 grams of C4/Generation 4

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C450X
Description: 12 grams of C450X

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 grams of flavored dextrose